iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC reduced its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 61.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 60,401 shares of the company's stock after selling 96,930 shares during the period. Nuveen Asset Management LLC owned about 0.17% of iTeos Therapeutics worth $464,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the business. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of iTeos Therapeutics by 90.5% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,589 shares of the company's stock worth $965,000 after acquiring an additional 59,649 shares in the last quarter. Millennium Management LLC boosted its holdings in iTeos Therapeutics by 1,008.8% in the fourth quarter. Millennium Management LLC now owns 411,072 shares of the company's stock valued at $3,157,000 after purchasing an additional 373,999 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in iTeos Therapeutics by 347.9% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 922,134 shares of the company's stock worth $7,082,000 after purchasing an additional 716,271 shares in the last quarter. Graham Capital Management L.P. acquired a new position in iTeos Therapeutics during the 4th quarter worth $85,000. Finally, Forefront Analytics LLC purchased a new stake in iTeos Therapeutics during the 4th quarter worth about $85,000. 97.16% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the company's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total value of $5,079,339.46. Following the completion of the sale, the insider now directly owns 2,108,594 shares of the company's stock, valued at $16,995,267.64. This represents a 23.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Ansbert Gadicke sold 1,031,931 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total value of $8,317,363.86. Following the transaction, the insider now owns 3,452,797 shares in the company, valued at $27,829,543.82. This represents a 23.01% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,843,142 shares of company stock worth $15,238,020. Corporate insiders own 12.50% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Wells Fargo & Company reiterated an "equal weight" rating and issued a $12.00 price objective (down previously from $13.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 28th. HC Wainwright cut shares of iTeos Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, May 14th. Wedbush downgraded shares of iTeos Therapeutics from an "outperform" rating to a "neutral" rating and lifted their price target for the stock from $10.00 to $12.00 in a research note on Wednesday, May 28th. Leerink Partnrs cut shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 14th. Finally, Piper Sandler restated an "overweight" rating and issued a $12.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Six analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, iTeos Therapeutics presently has a consensus rating of "Hold" and an average price target of $15.86.

iTeos Therapeutics Price Performance

Shares of NASDAQ ITOS traded down $0.01 during midday trading on Friday, hitting $10.17. 1,062,628 shares of the company's stock were exchanged, compared to its average volume of 659,625. iTeos Therapeutics, Inc. has a twelve month low of $4.80 and a twelve month high of $18.13. The company has a market cap of $389.25 million, a PE ratio of -3.23 and a beta of 1.39. The firm's fifty day simple moving average is $7.38 and its 200-day simple moving average is $7.47.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last announced its quarterly earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.14. Equities analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.